Loading provider…
Loading provider…
Neurology Physician in Berkeley, CA
NPI: 1558477018Primary Employer
Sutter East Bay Medical Foundation
sutterhealth.org
HQ Phone
Get M.D. Joanna's Phone Numberphone_androidMobile
Get M.D. Joanna's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1980 - 2026
NY State Medical License
2005 - 2015

American Board of Psychiatry and Neurology
Neurology

American Board of Psychiatry and Neurology
Sleep Medicine
Martinez Veterans Affairs Medical Center
Residency • Neurology
1980 - 1983
Alta Bates Summit Medical Center - Herrick campus
Internship • Transitional Year
1979 - 1980
Tel Aviv University Sackler
Medical School
Until 1975
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 153 | 192 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 135 | 191 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 97 | 156 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 70 | 84 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 61 | 61 |
Response of intrathecal baclofen resistance to dose reduction.
Authors: Joanna A. Cooper, Barbara Ridley
Publication Date: 2006-10
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
Authors: Eric Eggenberger, Revere Kinkel, Douglas Goodin, Steven Galetta
Journal: Neurology
Publication Date: 2006-01-25
Lead Sponsor: MedDay Pharmaceuticals SA
Intervention / Treatment: DRUG: PLACEBO, DRUG: MD1003 100mg capsule
Lead Sponsor: Avanir Pharmaceuticals
Intervention / Treatment: DRUG: Placebo, DRUG: AVP-923-45, DRUG: AVP-923-30, DRUG: AVP-923-20
Lead Sponsor: Acorda Therapeutics
Intervention / Treatment: OTHER: Placebo, DRUG: Dalfampridine-ER 10mg, DRUG: Dalfampridine-ER 5mg